The news was a major tonic for Merck, which is chasing close behind Opdivo with its rival PD-1 drug Keytruda (pemtruzumab) across a number of cancer types. Opdivo has established a clear lead so ...

Bristol-Myers Squibb's (BMS) Opdivo, the first in a new generation on immunotherapy cancer drugs approved to treat non-small cell lung cancer (NSCLC) has been rejected by NICE in draft guidance.

Different parts of Medicare can provide coverage for cancer ... Opdivo infusions that a person gets as an outpatient in a health center or doctor’s clinic. Medicare Part D covers prescription ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer. Opdivo (nivolumab) plus Yervoy (ipilimumab) improved ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.